Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancer

4Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Purpose. Patients with high-risk prostate cancer (PC) can be treated with high-dose intensity-modulated radiotherapy (IMRT) and long-term androgen deprivation (AD). In this paper we report on (i) late toxicity and (ii) biochemical (bRFS) and clinical relapse-free survival (cRFS) of this combined treatment. Methods. 126 patients with high-risk PC (T3-4 or PSA >20ng/mL or Gleason 8-10) and ≥24 months of followup were treated with high-dose IMRT and AD. Late toxicity was recorded. Biochemical relapse was defined as PSA nadir +2ng/mL. Clinical relapse was defined as local failure or metastases. Results. The incidence of late grade 3 gastrointestinal and genitourinary toxicity was 2 and 6, respectively. Five-year bRFS and cRFS were 73 and 86 respectively. AD was a significant predictor of bRFS (P = 0.001) and cRFS (P = 0.01). Conclusion. High-dose IMRT and AD for high-risk PC offers excellent biochemical and clinical control with low toxicity. Copyright © 2012 Valérie Fonteyne et al.

Cite

CITATION STYLE

APA

Fonteyne, V., Lumen, N., Villeirs, G., Ost, P., & De Meerleer, G. (2012). Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancer. Advances in Urology. https://doi.org/10.1155/2012/368528

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free